Karyopharm Therapeutics Inc.
Returns on Capital
| Fiscal Year | ROE | ROI | ROA |
|---|---|---|---|
| FY2021 | 155.7% | -138.5% | -40.6% |
| FY2022 | 992.4% | 992.4% | -46.1% |
| FY2023 | 105.1% | 105.1% | -59.5% |
| FY2024 | 41.1% | 41.1% | -46.5% |
| FY2025 | 66.9% | 66.9% | -180.8% |
Returns on Capital
| Fiscal Year | ROE | ROI | ROA |
|---|---|---|---|
| FY2021 | 155.7% | -138.5% | -40.6% |
| FY2022 | 992.4% | 992.4% | -46.1% |
| FY2023 | 105.1% | 105.1% | -59.5% |
| FY2024 | 41.1% | 41.1% | -46.5% |
| FY2025 | 66.9% | 66.9% | -180.8% |